Stages & Severity on Lung Diseases
There is no formal staging system for pulmonary fibrosis. Physicians use different factors, like the ones listed below, to describe the disease as mild, moderate, severe or very severe.
- Symptoms
- Pulmonary Function Test or Lung function Test
- Six minute walk test
- A high resolution CT scan
Related Conference of Stages & Severity on Lung Diseases
November 20-21, 2024
4th International Conference on Tuberculosis, Lung Health and Respiratory Diseases
Paris, France
Stages & Severity on Lung Diseases Conference Speakers
Recommended Sessions
Related Journals
Are you interested in
- Allergy testing and treatment in respiratory diseases - Euro Pulmonology 2024 (France)
- Asthma - Tuberculosis-2024 (France)
- Atelectasis and Pneumothorax - Tuberculosis-2024 (France)
- Bronchial thermoplasty for asthma management - Euro Pulmonology 2024 (France)
- Cardiopulmonary Disease - Tuberculosis-2024 (France)
- Chronic cough evaluation and treatment strategies - Euro Pulmonology 2024 (France)
- Chronic Obstructive Pulmonary Disease (COPD) - Tuberculosis-2024 (France)
- Climate Change and Respiratory Diseases - Tuberculosis-2024 (France)
- COVID-19 and its impact on respiratory health - Euro Pulmonology 2024 (France)
- Epidemiology of TB Disease - Tuberculosis-2024 (France)
- Gastroesophageal reflux disease (GERD) - Tuberculosis-2024 (France)
- Genetics of respiratory diseases and precision medicine - Euro Pulmonology 2024 (France)
- Imaging techniques in pulmonary medicine - Euro Pulmonology 2024 (France)
- Interstitial lung disease and lung transplant outcomes - Euro Pulmonology 2024 (France)
- Latent TB Infection and Active TB Disease - Tuberculosis-2024 (France)
- Lung cancer and personalized medicine approaches - Euro Pulmonology 2024 (France)
- Lung cancer screening and early detection programs - Euro Pulmonology 2024 (France)
- Lung Cancer: Screening, Diagnosis & Treatment - Tuberculosis-2024 (France)
- Lung Function in Men with and without HIV - Tuberculosis-2024 (France)
- Lung Infection - Tuberculosis-2024 (France)
- Lung microbiome and respiratory diseases - Euro Pulmonology 2024 (France)
- Multidrug-resistant TB - Tuberculosis-2024 (France)
- Mycobacterial Infections - Tuberculosis-2024 (France)
- Non-invasive ventilation techniques and outcomes - Euro Pulmonology 2024 (France)
- Occupational asthma and work-related respiratory diseases - Euro Pulmonology 2024 (France)
- Palliative Care for Advanced Lung Cancer - Tuberculosis-2024 (France)
- Pulmonary arterial hypertension diagnosis and management - Euro Pulmonology 2024 (France)
- Pulmonary Complications of Endocrine Diseases - Tuberculosis-2024 (France)
- Pulmonary Diseases and Therapeutics - Tuberculosis-2024 (France)
- Pulmonary drug delivery systems and innovations - Euro Pulmonology 2024 (France)
- Pulmonary Edema - Tuberculosis-2024 (France)
- Pulmonary edema pathophysiology and treatment - Euro Pulmonology 2024 (France)
- Pulmonary embolism diagnosis and management - Euro Pulmonology 2024 (France)
- Pulmonary rehabilitation in critically ill patients - Euro Pulmonology 2024 (France)
- Pulmonary sarcoidosis diagnosis and treatmen - Euro Pulmonology 2024 (France)
- Respiratory failure management in ICU patients - Euro Pulmonology 2024 (France)
- Respiratory syncytial virus updates and management - Euro Pulmonology 2024 (France)
- TB Clinical Trials - Tuberculosis-2024 (France)
- TB Diagnosis, Prevention & Treatment - Tuberculosis-2024 (France)
- TB Vaccines - Tuberculosis-2024 (France)
- TB-HIV Co-infections - Tuberculosis-2024 (France)
- Zoonotic TB - Tuberculosis-2024 (France)